Tue, Jun 3, 8:46 PM (9 days ago)
Coeptis Therapeutics Holdings, Inc. (COEP) filed a Form 10-K/A to amend its annual report for the fiscal year ended December 31, 2024. The amendment includes Exhibit 97, the Company’s Clawback Policy, which was omitted in the original filing. Additionally, the amendment provides updated certifications from the principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. The aggregate market value of the voting and non-voting common equity held by non-affiliates was $8,455,735.40 as of the last business day of the registrant’s most recently completed second fiscal quarter, based on the closing sale price of $5.78 reported on the Nasdaq Capital Market. The number of shares outstanding of each of the registrant’s classes of common stock as of March 26, 2025, was 36,089,917 shares of $0.0001 par value common stock. This amendment does not modify or update any financial statements or disclosures related to Items 307 and 308 of Regulation S-K. The original Form 10-K continues to speak as of the date of the original filing, and the Company has not updated the disclosures contained therein to reflect any events that occurred after the original filing other than as expressly indicated in this Amendment No. 1.